Fingolimod after natalizumab and the risk of short-term relapse

Neurology

Volumn 82, Issue 14, 2014, Pages 1204-1211

  Jokubaitis, Vilija G ^a,b   Li, Vivien ^b   Kalincik, Tomas ^a,b   Izquierdo, Guillermo ^c   Hodgkinson, Suzanne ^d   Alroughani, Raed ^e   Lechner Scott, Jeannette ^f   Lugaresi, Alessandra ^g   Duquette, Pierre ^h   Girard, Marc ^h   Barnett, Michael ⁱ   Grand'Maison, Francois ^j   Trojano, Maria ^k   Slee, Mark ^l   Giuliani, Giorgio ^m   Shaw, Cameron ⁿ   Boz, Cavit ^o   Spitaleri, Daniele L A ^p   Verheul, Freek ^q   Haartsen, Jodi ^r,s   Liew, Danny ^a   Butzkueven, Helmut ^a,b,r,s   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d LIVERPOOL HOSPITAL   (Australia)

^e AL AMIRI HOSPITAL   (Kuwait)

^f JOHN HUNTER HOSPITAL   (Australia)

^g UNIVERSITY OF CHIETI   (Italy)

^h NOTRE DAME HOSPITAL   (Canada)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j HÔPITAL CHARLES LEMOYNE   (Canada)

^k UNIVERSITY OF BARI   (Italy)

^l FLINDERS UNIVERSITY   (Australia)

^m Ospedale di Macerata   (Italy)

ⁿ GEELONG HOSPITAL   (Australia)

^o KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^p AORN San Giuseppe Moscati   (Italy)

^q GROENE HART HOSPITAL   (Netherlands)

^r Department of Neurology Eastern Health Victoria ^*  (Australia)

^s MONASH UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; FINGOLIMOD; GLATIRAMER; NATALIZUMAB;

ADULT; ARTICLE; DISEASE ACTIVITY; DRUG SUBSTITUTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; SURVIVAL;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; RECURRENCE; RISK FACTORS; SPHINGOSINE; TREATMENT OUTCOME;

EID: 84902165030     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000283     Document Type: Article

References (28)

1. Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate: modifiers of lymphocyte migration. N Engl J Med 2006;355:1088-1091.
2. David OJ, Kovarik JM, Schmouder RL. Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet 2012;51:15-28.
3. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
4. Devonshire V, Havrdova E, Radue EW, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the doubleblind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol 2012;11:420-428.
5. Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011;10:520-529.
6. Castrop F, Kowarik MC, Albrecht H, et al. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence? Neurology 2012;78:928-930.
7. Centonze D, Rossi S, Rinaldi F, Gallo P. Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology 2012;79:2004-2005.
8. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2008; 70:1150-1151.
9. Visser F, Wattjes MP, Pouwels PJ, Linssen WH, van Oosten BW. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 2012;79:2000-2003.
10. Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-747.
11. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-1140.
12. Butzkueven H, Chapman J, Cristiano E, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler 2006; 12:769-774.
13. O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009;72:73-79.
14. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011;68:186-191.
15. Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS: The UK Antegren Study Group. Neurology 1999;53:466-472.
16. Kerbrat A, Le Page E, Leray E, et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci 2011;308:98-102.
17. Havla J, Gerdes LA, Meinl I, et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 2011;258:1665-1669.
18. Jander S, Turowski B, Kieseier BC, Hartung HP. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler 2012;18:1650-1652.
19. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011; 10:745-758.
20. Sempere AP, Martin-Medina P, Berenguer-Ruiz L, et al. Switching from natalizumab to fingolimod: an observational study. Acta Neurol Scand 2013;125:e6-e10.
21. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
22. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011;76:1858-1865.
23. Stuve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 2009;72:396-401.
24. Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler 2012;18: 1640-1643.
25. Held U, Heigenhauser L, Shang C, Kappos L, Polman C. Predictors of relapse rate in MS clinical trials. Neurology 2005;65:1769-1773.
26. Fazekas F, Bajenaru O, Berger T, et al. How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis? Front Neurol 2013;4:10.
27. Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K. Fingolimod for the treatment of relapsing multiple sclerosis. Expert Rev Neurother 2011; 11:165-183.
28. de Seze J, Ongagna JC, Collongues N, et al. Reduction of the washout time between natalizumab and fingolimod. Mult Scler 2013;19:1248.